This EAP is available for indications where there is reasonable scientific basis for use. Availability will depend on territory eligibility.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient's disease is serious or life-threatening.
The patient has undergone appropriate standard treatments; there are no comparable or satisfactory alternative treatments for the disease or condition; the treatment is adjunct to an existing treatment option, and the treatment is not medically contra-indicated.
Sufficient efficacy and safety evidence exists to make a benefit-risk analysis consistent with this policy and the potential patient benefit justifies any potential risks of treatment.
Sufficient clinical data are available to identify an appropriate dose and treatment duration.
The patient's treating physician and qualified medical personnel at Agenus agree there is sufficient evidence to assume the potential benefit to the patient justifies potential risks.
You may not be if
Expanded Access will not adversely impact any clinical development program, in particular, the conduct of a pivotal clinical trial that is required for regulatory approval.
The request must be made by the patient's treating physician.
Clareo Health | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
